Cargando…

Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab

Class 1 and 2 monoclonal antibodies inhibit SARS-CoV-2 entry by blocking the interaction of the viral receptor-binding domain with angiotensin-converting enzyme 2 (ACE2), while class 3 antibodies target a highly conserved epitope outside the ACE2 binding site. We aimed to investigate the plasticity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magnus, Clara Luzia, Hiergeist, Andreas, Schuster, Philipp, Rohrhofer, Anette, Medenbach, Jan, Gessner, André, Peterhoff, David, Schmidt, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449809/ https://www.ncbi.nlm.nih.gov/pubmed/36090991 http://dx.doi.org/10.3389/fimmu.2022.966236

Ejemplares similares

The potential of herbal extracts to inhibit SARS-CoV-2: a pilot study
por: De Pellegrin, Michela Luisa, et al.
Publicado: (2021)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
por: Totschnig, David, et al.
Publicado: (2022)

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
por: Kreye, Jakob, et al.
Publicado: (2023)

Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals
por: Mader, Anna-Lena, et al.
Publicado: (2022)

In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys
por: Aweda, Tolulope A., et al.
Publicado: (2022)

Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination
por: Bauswein, Markus, et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS
por: Adachi, Eisuke, et al.
Publicado: (2022)

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
por: Gliga, Smaranda, et al.
Publicado: (2022)

Current Limitations for the Assessment of the Role of the Gut Microbiome for Attention Deficit Hyperactivity Disorder (ADHD)
por: Hiergeist, Andreas, et al.
Publicado: (2020)

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
por: Case, James Brett, et al.
Publicado: (2022)

Experience of the United Arab Emirates in the use of monoclonal antibody drug sotrovimab in high-risk vaccinated and unvaccinated patients with COVID-19: an observational cohort study
por: Abdalateef, Sumaya, et al.
Publicado: (2023)

SARS-CoV-2 evolution during persistent infection in a CAR-T recipient shows an escape to both sotrovimab and T-cell responses
por: Mazzetti, Paola, et al.
Publicado: (2023)

1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment of Early Mild-to-Moderate COVID-19
por: Gupta, Anil K, et al.
Publicado: (2022)

Health Tract No. 309: Comfort
Publicado: (1868)

Escape From Monoclonal Antibody Neutralization Affects Henipavirus Fitness In Vitro and In Vivo
por: Borisevich, Viktoriya, et al.
Publicado: (2016)

Catching the evader: Can monoclonal antibodies interfere with Staphylococcus aureus immune escape?
por: Rasigade, Jean-Philippe
Publicado: (2017)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
por: Ragonnet-Cronin, Manon, et al.
Publicado: (2023)

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
por: Gupta, Anil K, et al.
Publicado: (2021)

Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
por: Jaki, Lena, et al.
Publicado: (2023)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Publicado: (2022)

Reliability of species detection in 16S microbiome analysis: Comparison of five widely used pipelines and recommendations for a more standardized approach
por: Hiergeist, Andreas, et al.
Publicado: (2023)

Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants
por: ter Meulen, Jan, et al.
Publicado: (2006)

Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape
por: Krey, Thomas, et al.
Publicado: (2013)

Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins
por: Bruun, Tim-Henrik, et al.
Publicado: (2017)

Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
por: Gupta, Isha, et al.
Publicado: (2022)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

A monoclonal antibody that recognizes B cells and B cell precursors in mice
Publicado: (1981)

Isolation and Characterization of Lytic Proteus Virus 309
por: Aaron, Joshua, et al.
Publicado: (2022)

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
por: Zaqout, Ahmed, et al.
Publicado: (2022)

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants
por: Yokokawa, Hiroshi, et al.
Publicado: (2022)

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
por: Touret, Franck, et al.
Publicado: (2023)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Memorandum: Addendum to P309 and request for beamtime in 2000
por: Dubrovin, M S, et al.
Publicado: (1999)

Correction to Lancet Oncol 2018; 19: 295–309
Publicado: (2018)

Correction to Lancet Oncol 2021; 22: 309–20
Publicado: (2021)

Nectin-1 Expression Correlates with the Susceptibility of Malignant Melanoma to Oncolytic Herpes Simplex Virus In Vitro and In Vivo
por: Schwertner, Barbara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4i9oau5144trkddfsngk6iestk